BiotechTube

CGT9486 + Pexidartinib + Sunitinib

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Stromal Tumors

Trial Timeline

Mar 6, 2015 → May 11, 2020

NCT ID
NCT02401815

About CGT9486 + Pexidartinib + Sunitinib

CGT9486 + Pexidartinib + Sunitinib is a phase 1/2 stage product being developed by Cogent Biosciences for Gastrointestinal Stromal Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02401815. Target conditions include Gastrointestinal Stromal Tumors.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02401815Phase 1/2Completed

Competing Products

20 competing products in Gastrointestinal Stromal Tumors

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
52
Patritumab deruxtecanDaiichi SankyoPhase 1/2
41
DS-6157aDaiichi SankyoPhase 1
33
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
52
Naldemedine + PlaceboShionogiPhase 2
52
GemcitabineEli LillyPhase 1/2
41
OlaratumabEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 2
52
cetuximabEli LillyPhase 2
52
BBI503Sumitomo PharmaPhase 2
52
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
41
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
52
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
77
FamitinibJiangsu Hengrui MedicinePhase 2
52
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
77
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
77
EsomeprazoleAstraZenecaPhase 3
77
AZD2171AstraZenecaPhase 2
52

Other Products from Cogent Biosciences

CGT9486 plus sunitinib + CGT9486 + Sunitinib + Sunitinib + Midazolam + CGT9486 plus sunitinibPhase 3
74
Bezuclastinib in combination with sunitinibPhase 2
49
Bezuclastinib Tablets (Formulation A) + Bezuclastinib Tablets (Formulation B) + Placebo TabletsPhase 2
49
bezuclastinibPhase 2
49
CGT4859Phase 1/2
38